Choroid plexus meningioma is a rare, typically slow-growing brain tumor that arises near the fluid-making tissue in the brain. People with choroid plexus meningioma may have headaches, nausea, balance trouble, or vision changes, and doctors may see signs of raised pressure in the skull. It can occur at any age but is more often found in adults, and early symptoms of choroid plexus meningioma can be subtle. Treatment usually involves surgery, and radiation may be used if complete removal is not possible. Most people do well with treatment, but outcomes depend on tumor size, location, and overall health.
Overview
Choroid plexus meningiomaSymptoms
Choroid plexus meningioma often causes pressure-related symptoms from blocked cerebrospinal fluid flow. Early symptoms include headaches, nausea, vomiting, blurred vision, and dizziness. Some develop seizures, memory or concentration problems, weakness, or balance difficulties.
Outlook and prognosis
Most people with choroid plexus meningioma do well after tailored surgery, especially when the tumor is completely removed. Growth tends to be slow, and many remain stable for years with regular MRI check‑ins. If needed, focused radiation can help control regrowth.
Causes and risk factors
Choroid plexus meningioma usually occurs sporadically; the exact cause is unknown. Risk rises with prior head radiation, NF2-related inherited changes, and age. Female sex, pregnancy or estrogen therapy, plus obesity and family history, may further increase risk.
Genetic influences
Genetics play a limited role in most choroid plexus meningiomas. Sporadic cases are common, but changes in tumor-suppressor genes (often NF2) can drive growth. Rarely, inherited conditions like neurofibromatosis type 2 increase risk; genetic counseling may help families.
Diagnosis
Doctors start with a neurological exam and brain MRI (with contrast), sometimes CT. The diagnosis of choroid plexus meningioma is confirmed by imaging features and, when needed, tissue pathology from surgery or biopsy.
Treatment and drugs
Treatment for choroid plexus meningioma usually centers on surgery to remove as much of the tumor as is safely possible. When needed, focused radiation (such as stereotactic radiosurgery) can help control small remnants or recurrences. Care teams also manage symptoms like headaches or vision changes and monitor with regular MRI scans.
Symptoms
Choroid plexus meningioma can cause symptoms by blocking the normal flow of brain fluid (cerebrospinal fluid) and pressing on nearby brain areas. Early symptoms of choroid plexus meningioma often include headaches and subtle changes in vision or thinking. Symptoms vary from person to person and can change over time. Depending on location and size, people may notice nausea, balance problems, or weakness on one side.
Headaches that are worse in the morning or with coughing can point to raised pressure in the head. Some feel a deep, squeezing ache that eases after sitting up. With choroid plexus meningioma, this can come from fluid buildup or blockage.
Feeling sick to your stomach or throwing up can happen with higher pressure inside the skull. It may flare in the morning or after sudden movements. Treatment that lowers pressure often eases this.
Blurry or double vision can appear when pressure affects the optic nerves. You might notice brief dimming, trouble focusing, or a new blind spot when reading. With choroid plexus meningioma, swelling around the eyes’ nerves can be a cause.
Slower thinking, trouble concentrating, or forgetfulness can creep in. Tasks that once felt automatic may take extra effort or more time. Family members may see patterns the person doesn’t.
How people usually first notice Choroid plexus meningioma?
Many people first notice a choroid plexus meningioma when persistent headaches, nausea, or episodes of vomiting don’t ease with usual remedies, sometimes joined by blurry or double vision or brief spells of confusion. Because these tumors sit in the brain’s fluid-filled spaces, they can block fluid flow and raise pressure inside the skull, so the first signs of choroid plexus meningioma often look like pressure symptoms rather than a discrete “lump,” and a sudden worsening headache or new neurologic change typically prompts brain imaging. In children, how choroid plexus meningioma is first noticed may include a rapidly enlarging head size or irritability, while adults more often report headaches and visual changes that lead to an MRI or CT scan and the diagnosis.
Types of Choroid plexus meningioma
Choroid plexus meningioma is rare, and doctors classify it the same way they do other meningiomas—mainly by how the tumor cells look under the microscope and how fast they tend to grow. These variants can lead to differences in pace of growth, chances of coming back after surgery, and the kinds of symptoms people notice day to day, such as headaches, vision changes, or memory trouble from pressure on nearby brain pathways. Clinicians often describe them in these categories: tumor grade (benign, atypical, anaplastic) and certain histologic patterns that behave a bit differently. If you’re comparing types of choroid plexus meningioma, the key differences are growth behavior, recurrence risk, and how strongly they press on fluid spaces in the brain, which can drive early symptoms of choroid plexus meningioma like worsening headaches or nausea.
Grade I (benign)
These tumors grow slowly and are less likely to invade nearby tissue. Symptoms often build gradually from fluid buildup or pressure effects, and surgery is commonly effective. Follow-up scans are still important to watch for regrowth.
Grade II (atypical)
These tumors grow faster than Grade I and have a higher chance of coming back after treatment. People may notice symptoms progress over weeks to months, and doctors often consider radiation after surgery. Close imaging follow-up is standard.
Grade III (anaplastic)
These are aggressive and can invade surrounding structures, with the highest recurrence risk. Symptoms can escalate quickly, including severe headaches, vomiting, or neurologic changes from rapid pressure shifts. Treatment usually combines surgery and radiation, and sometimes additional therapies.
Syncytial (meningothelial)
This common histologic pattern forms solid sheets of cells and often behaves like other Grade I tumors. Symptoms may center on pressure-related headaches and vision changes when the tumor narrows fluid pathways. Outcomes are generally favorable with complete removal.
Fibrous (fibroblastic)
These tumors contain more connective tissue-like strands and can feel firmer during surgery. They typically grow slowly, but firmness may affect how easily they can be fully removed. Recovery and recurrence risk depend on how complete the resection is.
Transitional (mixed)
These show a mix of syncytial and fibrous features under the microscope. Growth is usually slow to moderate, and symptoms can mirror other lower-grade types. Prognosis tends to be good if the entire tumor is removed.
Secretory variant
This rare type can produce protein-rich fluid inside the tumor and sometimes around it. People may have disproportionate swelling and pressure symptoms compared with the tumor’s size, such as morning headaches or nausea. Management often includes addressing fluid buildup along with tumor removal.
Clear cell variant
This variant can behave more aggressively and may be graded higher based on its features. Symptoms may evolve faster, and the chance of recurrence is higher than in typical Grade I types. Doctors often plan more frequent imaging and may add radiation.
Angiomatous variant
These tumors have many blood vessels, which can influence surgical planning due to bleeding risk. Symptoms often relate to pressure, but vascularity may cause more swelling around the tumor. Preoperative strategies sometimes aim to reduce blood flow before removal.
Psammomatous variant
These have many tiny calcium deposits called psammoma bodies. They tend to grow slowly, and calcification can make them appear dense on imaging. Symptoms often reflect long-standing pressure rather than rapid change.
What genetics can tell you about symptoms
Some people with inherited NF2 gene changes develop choroid plexus meningiomas earlier, with headaches, vision changes, or balance problems from pressure on nearby brain structures. Rare SMARCE1 variants can also be linked, often bringing slower-growing tumors that still cause headaches or seizures.
Causes and risk factors
The exact cause of choroid plexus meningioma is unclear, and risks do not always predict early symptoms of choroid plexus meningioma.
Prior head radiation and older age increase risk.
Female sex and hormones, including pregnancy or menopausal hormone therapy, may influence growth, and higher body weight may add risk.
A small number are linked to inherited changes, such as a condition called neurofibromatosis type 2.
Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Choroid plexus meningioma is a rare brain tumor that can disrupt daily routines when it presses on nearby brain pathways. Doctors often group risks into internal (biological) and external (environmental). Knowing these can help you understand what may raise risk, especially if early symptoms of choroid plexus meningioma appear.
Exposure to high-dose head or neck radiation increases the chance of meningioma, including choroid plexus meningioma. Past medical radiotherapy is the most common source; accidental or environmental exposures are far less common. Modern diagnostic imaging uses much lower doses today.
Radiation to the head during childhood carries a stronger long-term risk than the same doses in adulthood. This higher sensitivity can set the stage for a tumor decades later, including choroid plexus meningioma.
Meningiomas are more common in women, and this pattern is also seen for tumors inside the brain’s fluid spaces. Hormonal biology likely contributes to this difference.
Natural changes in estrogen and progesterone across life stages may influence whether a meningioma forms or how fast it grows. Pregnancy can temporarily speed growth of an existing tumor rather than create one.
Genetic risk factors
For people diagnosed with choroid plexus meningioma, genes can shape why the tumor develops and how it behaves. Carrying a genetic change doesn’t guarantee the condition will appear. Most risks are changes that appear only in the tumor cells (somatic), while a smaller share come from inherited variants present from birth. Understanding genetic risk factors for choroid plexus meningioma can help tailor testing and follow-up.
NF2 gene changes: Changes in the NF2 gene are a common driver of meningiomas across locations. They often involve losing part of chromosome 22, which removes a natural brake on cell growth. This pattern can be found in some choroid plexus meningioma tumors.
Non-NF2 drivers: Some tumors instead carry changes in genes such as TRAF7, KLF4, AKT1, SMO, PIK3CA, or POLR2A. These are usually acquired only in the tumor cells, not inherited. They can influence where the tumor grows and its behavior.
TERT promoter changes: Alterations in the TERT promoter can make cells keep dividing. When present in choroid plexus meningioma, they may be linked with faster growth or a higher chance of return. Doctors may check for this to guide follow-up.
Inherited NF2 syndrome: A harmful NF2 variant passed in families raises the chance of multiple meningiomas. People may develop tumors in the brain or spine at younger ages. This can include, occasionally, choroid plexus meningioma.
SMARCE1 variants: Rare inherited changes in SMARCE1 predispose to clear cell meningiomas, often in children or young adults. More than one family member may be affected. Genetic counseling can help families understand testing options.
SMARCB1 variants: Inherited SMARCB1 changes can underlie familial meningioma. People may develop several tumors over time. Confirming the gene change can guide monitoring for relatives.
BAP1 tumor syndrome: Pathogenic BAP1 variants raise the risk of a rare, more aggressive meningioma subtype. Finding this change may shape treatment intensity and follow-up. Relatives might also be offered testing because it is inherited.
Family history: Having a close relative with meningioma modestly increases personal risk even when no single gene is found. How much risk changes from one family to another can vary widely. Doctors may discuss periodic checks if several relatives are affected.
Chromosome copy changes: Losses or gains of DNA on chromosomes such as 1p or 14q can build up in tumor cells. These are not inherited but can signal higher-risk tumor biology. They help doctors estimate the chance a choroid plexus meningioma could return.
Mosaic NF2: In mosaic NF2, the gene change is present in only some of the body’s cells from early development. People may have multiple meningiomas with few external signs of the syndrome. Testing both blood and tumor tissue can improve detection.
Lifestyle risk factors
Choroid plexus meningioma is rare, so most lifestyle data come from studies of meningiomas overall. Lifestyle habits do not cause these tumors outright, but certain choices may influence the chances of developing a meningioma and can affect symptoms or recovery if you have one. Below are lifestyle risk factors for Choroid plexus meningioma based on the broader meningioma literature, with practical ways they may impact risk or outcomes. This addresses how lifestyle affects Choroid plexus meningioma without covering environmental or genetic factors.
Higher body mass index is linked to a greater risk of meningioma, likely through higher estrogen, insulin, and IGF-1 signaling that can support tumor growth. Gradual weight loss through diet and activity may lower these hormonal drivers and could help reduce growth pressures on a tumor.
Lower physical activity is associated with higher meningioma risk in observational studies. Regular moderate exercise improves insulin sensitivity and inflammation, which may create a less growth-permissive environment and can ease fatigue and cognition issues during recovery.
Long-term use of estrogen- or progestin-containing therapies (such as some HRT or contraceptives) has been linked to higher meningioma risk in some studies. Reviewing dose, duration, and alternatives with a clinician may reduce hormone exposure that could influence tumor behavior.
Diets high in refined carbohydrates and added sugars can raise insulin and IGF-1, pathways implicated in meningioma biology. Emphasizing vegetables, whole grains, legumes, and unsweetened foods helps steady insulin signaling and may lessen metabolic drivers of tumor growth.
Risk prevention
Choroid plexus meningioma is rare, and there’s no sure way to prevent it, but you can lower some risks. Prevention is about lowering risk, not eliminating it completely. The strongest links are exposure to ionizing radiation, certain hormone medicines, and higher body weight. It also helps to know the early symptoms of choroid plexus meningioma so you can seek care promptly if something feels off.
Avoid nonessential head CT scans and ask if MRI or ultrasound could answer the question instead. If imaging is needed, use the lowest dose and protective shields, especially for children.
Talk with your clinician about the risks and benefits of long-term hormone therapy or high‑dose progestins. Using the lowest effective dose and regular check-ins may help reduce meningioma risk.
Higher body weight has been linked to a greater chance of meningioma. Small, steady steps toward a balanced diet and daily movement can help lower risk.
Early symptoms of choroid plexus meningioma can include morning‑worse headaches, nausea, blurry vision, or balance problems from fluid buildup in the brain. If new, persistent symptoms appear, seek medical care promptly.
Transmission
Choroid plexus meningioma is not contagious and cannot be transferred from one person to another. It arises from the coverings around the brain and, for most people, develops sporadically without a family link. In a small number of families, a tendency to form meningiomas can be inherited, most often as part of a condition called neurofibromatosis type 2 (NF2); even then, the tumor itself is not passed on—only the increased risk. If you’re wondering about the genetic transmission of choroid plexus meningioma or how choroid plexus meningioma is inherited, this is rare, and genetic counseling may be considered when there is a strong family history.
When to test your genes
Choroid plexus meningioma is rare, so broad genetic testing isn’t routine. Consider testing if you were diagnosed at a young age, have multiple or recurrent meningiomas, a family history of meningioma/nerve sheath tumors, or features suggesting NF2-related schwannomatosis; results can guide surveillance, imaging intervals, and surgical or radiation planning.
Diagnosis
People with choroid plexus meningioma often notice headaches, nausea, or vision changes that build over time as pressure inside the skull rises. Getting a diagnosis is often a turning point toward answers and support. The diagnosis of choroid plexus meningioma typically starts with a focused neurologic exam and brain imaging, with MRI providing the clearest picture. From there, specialists use a combination of scans and, when needed, tissue testing to confirm the exact tumor type and guide treatment.
Doctors usually begin with a symptom review and a neurologic exam to check vision, balance, memory, and reflexes. These findings help decide which tests to order first. They also point to signs of pressure build-up from blocked fluid flow.
MRI shows where the tumor sits inside the ventricle and how it affects nearby brain structures. A choroid plexus meningioma often appears as a well-defined, strongly enhancing mass at the ventricular trigone. MRI also helps plan surgery by mapping critical pathways.
CT can quickly show a solid mass, calcium deposits, and any bleeding. It is useful in urgent settings and complements MRI findings. CT also helps assess bone changes if the tumor abuts the ventricle walls.
An eye doctor may look for swelling of the optic nerves, called papilledema, which suggests increased brain pressure. Vision testing can document blind spots or double vision related to the tumor’s location. These features guide urgency and follow-up.
Stages of Choroid plexus meningioma
Choroid plexus meningioma does not have defined progression stages. Instead, these tumors are described by their size, location in the ventricle, and microscopic grade, and their course varies—some grow slowly while others can change more quickly. Early symptoms of choroid plexus meningioma, like headaches, memory changes, or vision issues, often prompt brain imaging that leads to diagnosis. Different tests may be suggested to help confirm the diagnosis and plan treatment, including MRI scans, eye and neurological exams, and sometimes surgical biopsy to determine the tumor’s grade.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after hearing the words choroid plexus meningioma. These tumors are typically slow-growing and benign, and many people do well after treatment, particularly when surgery can remove the tumor completely. Recurrence risk is generally low with a full resection, though it can be higher if only part of the tumor can be removed or if the tumor shows atypical features under the microscope. Early care can make a real difference, including managing pressure in the brain and preventing complications like hydrocephalus.
Looking at the long-term picture can be helpful. Most people with choroid plexus meningioma return to regular routines over weeks to months after surgery, and many resume work, study, or caregiving with few lasting effects. When tumors are harder to remove fully, focused radiation may be used to reduce the chance of regrowth, and follow-up scans are important for several years. Mortality from choroid plexus meningioma is uncommon in adults when timely treatment is available; risks tend to relate to tumor size, location, and surgical complexity rather than the tumor turning cancerous.
The outlook is not the same for everyone, but most people experience a stable course once the tumor is treated and swelling resolves. Early symptoms of choroid plexus meningioma—like headaches, nausea, or vision changes from increased pressure—often improve after surgery as the pressure normalizes. If a tumor returns, it is usually detected on routine imaging while small, when additional treatment is more effective. Talk with your doctor about what your personal outlook might look like, including your surgical plan, pathology details, and the schedule for follow-up MRI scans.
Long-term effects
Choroid plexus meningioma is usually slow-growing, and many people do well after surgery, especially when the tumor can be fully removed. Long-term effects vary widely and depend on tumor size, location inside the ventricles, and the type of treatment used. Some people return to their usual routines with little change, while others notice lasting issues like headaches, balance troubles, or thinking fatigue over time. Doctors may track these changes over years to see how recovery is holding steady or if anything new appears.
The chance of the tumor coming back is generally low after complete removal but higher if any tumor remains. Choroid plexus meningioma that recurs may do so slowly, sometimes over several years.
Because these tumors sit in the fluid spaces of the brain, long-term fluid buildup can persist or recur. Some people need a shunt to drain fluid, which may require adjustments over time.
Seizures can continue or newly appear after treatment, especially if the brain was irritated by surgery or swelling. Many find seizures become less frequent with medication, but some need ongoing follow-up.
Attention, memory, or processing speed can stay slower than before, even when scans look stable. For many, these thinking changes are mild but noticeable during multitasking or long workdays.
How is it to live with Choroid plexus meningioma?
Living with choroid plexus meningioma often means juggling uncertainty with routine, because symptoms can ebb and flow—headaches, nausea, memory lapses, or balance problems may interrupt work, school, or caregiving, especially if pressure inside the skull rises. Many need scans over time, surgery, or other treatments, which can bring fatigue, short-term thinking or mood changes, and time away from daily activities. Family, friends, and coworkers may notice slower processing, irritability, or sensory sensitivity after treatment and can help by pacing conversations, offering rides, and sharing practical tasks. With a care plan, rehabilitation, and symptom management, many regain steady ground and return to most activities, though listening to the body and planning extra recovery time becomes part of everyday life.
Treatment and drugs
Treatment for choroid plexus meningioma focuses first on safely removing the tumor when possible, since surgery often offers the best chance to ease pressure symptoms like headaches, vision changes, or balance problems. Surgeons plan the approach based on the tumor’s size, location inside the brain’s fluid spaces, and how close it sits to delicate blood vessels and nerves. If a small portion remains or if the tumor shows signs it may grow back, doctors may add focused radiation, such as stereotactic radiosurgery, to target the leftover cells while sparing nearby tissue. Medicines don’t shrink a choroid plexus meningioma, but they can help manage symptoms like seizures or swelling; a doctor may adjust your dose to balance benefits and side effects. Follow-up MRI scans are part of long-term care to watch for regrowth and guide any future treatment.
Non-drug treatment
Many living with choroid plexus meningioma want options that ease symptoms and protect everyday activities like reading, working, or driving. Care plans are tailored to the tumor’s size, location, growth speed, and your overall health, and early symptoms of choroid plexus meningioma can guide when to act versus when to monitor. Non-drug treatments often lay the foundation for care, sometimes before or alongside medicines. The elements below focus on surgeries, radiation, and supportive therapies that help you function and feel better day to day.
Regular MRI scans track the tumor over time. This approach suits small, stable choroid plexus meningioma when symptoms are mild or absent.
Surgeons aim to take out as much tumor as safely possible. This can relieve pressure-related symptoms like headaches, nausea, or vision changes.
Focused radiation targets the tumor in one or a few sessions. It may slow or stop growth of a choroid plexus meningioma without an incision.
Lower-dose radiation is given over several weeks. This can be useful when the tumor lies close to sensitive brain structures.
Your genes may have an impact on how drugs work for you
Some medicines for choroid plexus meningioma—and for symptoms like seizures or pain—work differently depending on genes that control how fast your liver processes drugs. Genetic testing can sometimes guide dosing or drug choice to improve benefit and limit side effects.
Pharmacological treatments
For choroid plexus meningioma, medicines mainly support symptoms and prepare you for surgery or radiation, which are the primary treatments. A few drug options may be considered when surgery or radiation aren’t possible, but evidence is limited and use is often off‑label. Not everyone responds to the same medication in the same way. Your team will tailor choices based on symptoms like headaches, nausea, or seizures and on overall health.
This can shrink swelling around the tumor to ease headaches and pressure symptoms. It’s usually used short term before or after procedures to help brain function. Doctors taper the dose to reduce side effects like high blood sugar or mood changes.
This helps prevent or calm seizures that can occur with choroid plexus meningioma. Dosing may be increased or lowered gradually to balance seizure control with side effects. Other options include lamotrigine or lacosamide if needed.
Acetaminophen or, if appropriate, an NSAID such as ibuprofen can help with tumor-related headaches. Stronger options like short courses of opioids may be used after surgery if pain is severe. Your team will aim for the lowest effective dose.
This reduces nausea and vomiting, which can be early symptoms of choroid plexus meningioma. Metoclopramide or prochlorperazine are alternatives if queasiness persists. Let your team know if you feel drowsy or constipated.
Genetic influences
Most choroid plexus meningiomas are not inherited; they usually develop when tumor cells pick up gene changes over time rather than from a gene change you were born with. Rarely, an inherited condition such as neurofibromatosis type 2 (NF2) can raise the chance of multiple meningiomas, including tumors inside the brain’s ventricles near the choroid plexus. In these situations, a change present from birth makes certain protective genes less effective, which can set the stage for tumor growth later on. Family history is one of the strongest clues to a genetic influence. If you were diagnosed at a young age, have more than one meningioma, or have relatives with similar tumors, your care team may discuss your genetic risk for choroid plexus meningioma and, in some cases, recommend counseling and testing to look for an inherited cause. Even when a hereditary syndrome isn’t found, testing the tumor itself can identify acquired gene changes that may help clarify prognosis and guide follow-up.
Is Choroid plexus meningioma genetic?
Genetics play a limited role in most choroid plexus meningiomas. Sporadic cases are common, but changes in tumor-suppressor genes (often NF2) can drive growth. Rarely, inherited conditions like neurofibromatosis type 2 increase risk; genetic counseling may help families.
Pharmacogenetics—how genetics influence drug effects
For treatment planning, doctors may look at the tumor’s DNA to see specific changes that could guide care for choroid plexus meningioma. Tumor profiling can find changes such as NF2 loss or shifts in growth pathways like Hedgehog or PI3K–AKT; in some cases, this information helps match people to targeted medicines or clinical trials if surgery and radiation are not enough. These targeted options remain under study in meningioma, but knowing whether the tumor carries a drug target can steer choices toward therapies that fit the biology of your tumor. Your own inherited genes can also affect supportive medicines used around treatment, including anti-seizure drugs, pain relievers, and steroids; some people process these medicines faster or slower because of enzyme differences, which can change dose needs and side effect risk. Genetics is only one factor, though—tumor size, location, prior treatments, and overall health also shape which drugs are used and how well they work. If you’re considering genetic testing for choroid plexus meningioma, ask whether both tumor profiling and, when appropriate, pharmacogenetic testing for drug-processing genes could inform choices now or in the future.
Interactions with other conditions
Choroid plexus meningioma sits within the brain’s fluid spaces, so it often intersects with conditions that affect cerebrospinal fluid flow. For many, this can mean that hydrocephalus or a preexisting tendency to fluid buildup becomes worse, raising pressure and sometimes intensifying headaches, balance changes, or early symptoms of choroid plexus meningioma like nausea and vision strain. People with neurofibromatosis type 2 (NF2) have a higher chance of developing multiple meningiomas, and the presence of other NF2‑related tumors can complicate imaging follow‑up and surgical planning. Hormonal factors matter, too: certain long‑term progestin medicines have been linked to meningioma growth, so clinicians may adjust contraception, hormone therapy, or prostate treatments when a tumor is present. Blood thinners and antiplatelet drugs for heart or stroke conditions can raise bleeding risk around surgery or rarely within the tumor, while preexisting epilepsy may see more frequent seizures if the tumor irritates nearby brain tissue. Ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden headaches, vision changes, and unsteady walking that today we’d recognize as pressure building inside the head. Families and communities once noticed patterns: an older relative with chronic headaches and slow, subtle personality changes, a parent who developed double vision, a grandparent whose balance faded over months. Looking back helps explain why these experiences were often blamed on “age” or “nerves,” because the growths causing them were hidden deep within the brain’s fluid spaces.
First described in the medical literature as meningiomas arising near the choroid plexus—the tissue that makes cerebrospinal fluid—these tumors were initially understood only through symptoms, later confirmed during surgery or at autopsy. Early surgeons sometimes reached them only after signs of increased pressure became severe. Reports from the late 19th and early 20th centuries detailed slow‑growing masses tucked in the lateral or fourth ventricles, where even a small tumor could block fluid flow and cause hydrocephalus.
As medical science evolved, brain imaging reshaped the story of choroid plexus meningioma. Pneumoencephalography and angiography offered the first indirect glimpses, but it was the arrival of CT in the 1970s and MRI in the 1980s that allowed doctors to see these tumors clearly before operating. This shift moved diagnosis from late recognition to earlier detection, often when people sought care for headaches, memory lapses, or changes in gait. Surgeons refined approaches to reach deep ventricular spaces more safely, and anesthesia and neuro‑monitoring lowered the risks that once limited treatment.
Over time, descriptions became more precise. Pathologists noted how these tumors attach to the delicate lining around the choroid plexus and tend to grow slowly. They distinguished them from other choroid plexus tumors that behave differently, especially in children. With each decade, classifications improved, guiding surgeons and radiation teams to tailor care based on location, size, and growth pattern rather than a one‑size‑fits‑all plan.
In recent decades, knowledge has built on a long tradition of observation. Advances in genetics identified changes common to meningiomas, such as alterations in genes that help regulate cell growth, while also highlighting that choroid plexus meningioma follows the overall pattern of being typically benign and slow‑growing. This understanding supports measured follow‑up for small, quiet tumors and timely treatment when they start to press on brain pathways or block fluid flow.
Not every early description was complete, yet together they built the foundation of today’s knowledge. For many living with choroid plexus meningioma, this history translates into clearer imaging, safer surgery, and more personalized decisions—often made before symptoms become overwhelming.